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In the current issue of the Journal, Klein and Machell (1)
again bring into focus the problem of managing patients with
coronary artery disease and documented nonsustained ven-
tricular tachycardia . As they point out, and as summarized
recently (2), several studies have shown that frequent and
complex ventricular ectopic activity in patients with a prior
myocardial infarction is an independent marker of an in-
creased risk of sudden cardiac death . Yet, many patients
with coronary artery disease and nonsustained ventricular
tachycardia never develop a sustained ventricular tachyar-
rhythmic event. Which of these patients are at risk for
sudden cardiac death and how best to treat them remain
controversial issues. Klein and Machell suggest that, in a
subgroup of patients with coronary artery disease and non-
sustained ventricular tachycardia (defined as >_5 beats of
monomorphic ventricular tachycardia at a rate > 120 beats/
min terminating spontaneously within 30 s), electrophysio-
logic testing may further stratify the risk of a patient for
sudden cardiac death and guide therapy .
The current study . In their study (1) of programmed
electrophysiologic stimulation in 40 patients with nonsus-
tained monomorphic ventricular tachycardia and coronary
artery disease, all 18 patients in whom ventricular tachycar-
dia was not induced subsequently remained free of sponta-
neous sustained ventricular tachyarrhythmia . However, a
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strikingly high percentage (22 patients [58%]) had inducible
monomorphic ventricular tachycardia (sustained in 17 and
nonsustained in 5). Drug therapy based on the results of
electrophysiologic testing was superior to drug therapy
guided empirically or by Hotter electrocardiographic (ECG)
monitoring . Of the 22 patients with induced ventricular
tachycardia, 7 (64%) of 11 receiving either empiric therapy
or Hotter monitor-guided therapy later developed an ar-
rhythmic event (sudden cardiac death or ventricular tachy-
cardia) compared with only 2 (18%) of 11 receiving therapy
guided by electrophysiologic testing .
Thus, Klein and Machell (1) seem to have defined a group
of patients with nonsustained ventricular tachycardia who
have a high incidence of inducible ventricular tachycardia .
Furthermore, during the mean follow-up period of 14 months
(range I to 57), their patients with coronary artery disease
and no inducible ventricular tachycardia were at remarkably
low risk for a spontaneous arrhythmic event (in fact, there
were none) .
Limitations of the study . Although the results of this
study have important implications, these data should be
interpreted with caution, Study design, limited follow-up
time and the small number (i .e ., 40) of patients studied
temper the conclusions that can be drawn . In addition, in
many patients (15 [38%] of 40), antiarrhythmic therapy was
not guided by electrophysiologic testing . For instance, four
patients with no inducible ventricular tachycardia were
treated with antiarrhythmic drugs . Had these patients not
been treated and subsequently experienced an arrhythmic
event, interpretation of the study would have been impor-
tantly influenced . Furthermore, because the study was not
placebo controlled, neither the incidence of proarrhythmia
(clearly a potential outcome of treatment) nor the actual
incidence of spontaneous arrhythmic events can be deter-
mined. In any event, the incidence (  [41%] of 22) of
spontaneous ventricular tachycardia was troublesomely
high, despite treatment, in the patients with inducible tachy-
cardia .
Although Klein and Machell (1) performed multivariate
analysis to determine predictors of inducible ventricular
tachycardia, they did not analyze which factors predicted
subsequent arrhythmic events . In addition, they did not
address the extent and treatment of myocardial ischemia or
the presence of a signal-averaged ECG late potential, which
are thought to predict arrhythmic events (3,4) .
Clinical implications . The most important contribution of
the Klein and Machell study (1) may be the identification of
a unique subgroup of patients with nonsustained ventricular
tachycardia and a high incidence of inducible ventricular
tachycardia . The authors' implicit assumption was that this
subgroup would also have a high incidence of spontaneous
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ventricular tachyarrhythmia . But without a placebo-
controlled study with a sufficient number of patients, we
cannot be certain . Additionally, the definition of spontane-
ous nonsustained ventricular tachycardia (>5 monomorphic
ventricular beats up to 30 s in duration at a rate > 120
beats/min) is different from that used for most previous
epidemiologic and electrophysiologic studies (>_3 ventricular
beats, not necessarily monomorphic, up to 30 s in duration at
a rate >100 beats/min) . One wonders if patients with coro-
nary artery disease who have runs of 3 or 4 beats of
nonsustained ventricular tachycardia regardless of QRS
complex configuration and at rates as slow as 100 beats/min
are really different from those with >_5 beats of monomor-
phic QRS complex configuration at rates >_ 120 beats/min .
Most monomorphic ventricular tachyarrhythmias are reen-
trant rhythms . Therefore, it should probably not be surpris-
ing that patients who had long runs (the range was 5 to 48
beats) of spontaneous, monomorphic, nonsustained ventric-
ular tachycardia with a previous myocardial infarction,
decreased ejection fraction and left ventricular wall motion
abnormalities had a high incidence of induction of ventricu-
lar tachycardia and even an important incidence of subse-
quent spontaneous sustained ventricular tachyarrhythmia .
Ultimately, the data from this article only suggest an-
swers to which of these patients are at risk for sudden
cardiac death and how best to treat them . We submit that it
is likely that Klein and Machell (1) have identified a subset of
patients with coronary artery disease who have a remarkably
high incidence of inducible, and potentially spontaneous,
sustained ventricular tachvcardia . Although it is reasonable
to assume that these high risk patients should be treated,




there are no definitive data to prove that treatment will affect
outcome . The high incidence of arrhythmic events in the
treated group of this study underscores the need to deter-
mine conclusively that treatment is indicated .
Conclusions. Thus, in our judgment, a careful, prospec-
tive, placebo-controlled study of patients with coronary
artery disease and nonsustained ventricular tachycardia is
needed to provide a sound basis for treatment . Importantly .
such a study should risk-stratify patients for outcome ac-
cording to variables traditionally thought to predict arrhyth-
mic events (including left ventricular ejection fraction, his-
tory of myocardial infarction, left ventricular wall motion
abnormalities, myocardial ischemia, presence of a signal-
averaged ECG late potential and induction of sustained
monomorphic ventricular tachycardia at electrophysiologic
study) . Although we are unaware that such a study is in the
offing, the clinical problem is clear and the need is great .
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